Scholarlink

<p>The bone marrow microenvironment influences acute myeloid leukemia (AML) progression. Mesenchymal stem cell–like (MSC-l)&#xa0;populations may exert tumor-modulating effects, but their prognostic role remains uncertain. We retrospectively analyzed 65 adult AML patients (excluding acute promyelocytic leukemia) treated with intensive chemotherapy between 2017 and 2024 at four Spanish institutions. MSC-l cells were identified in BM aspirates at end of treatment by multiparameter flow cytometry (CD13<sup>bright</sup>/CD45<sup>low</sup>/CD34<sup>neg</sup>/CD117<sup>neg</sup>/CD11b<sup>neg</sup>/CD16<sup>neg</sup>/CD71<sup>neg</sup>/CD64<sup>neg</sup>). Patients were stratified using a 0.265%cutoff (MSC-l<sup>HIGH</sup> ≥ 0.265% and MSC-l<sup>LOW</sup> &lt; 0.265%). Survival was assessed with Kaplan–Meier and Cox regression, adjusting for age and ELN 2017 risk. MSC-l<sup>HIGH</sup> patients had inferior overall survival (OS) (median 0.66&#xa0;years vs. not reached; <i>P</i> &lt; 0.001) and relapse-free survival (RFS) (median 1.27&#xa0;years vs. 1.49&#xa0;years;<i> P</i> = 0.027). These associations persisted across ELN risk groups. Multivariate analysis confirmed MSC-l<sup>HIGH</sup> status as an independent predictor of worse OS (HR = 6.43; 95% CI 2.53–16.33; <i>P</i> &lt; 0.001) and RFS (HR = 4.8; 95% CI 1.71–13.47; <i>P</i> = 0.003). MSC-l levels were lower in patients receiving myeloablative conditioning compared with non-transplanted patients, suggesting transplant intensity may influence MSC dynamics. Higher post-treatment MSC-l proportions are associated with poorer survival, independent of ELN risk and age, supporting their potential as a prognostic biomarker in AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Tamara Castaño-Bonilla,
  • Daniel Láinez-González,
  • Juana Serrano,
  • Mireia Atance,
  • Raquel Mata,
  • Cristina Serrano,
  • Rocío Olivera,
  • Rocío Salgado,
  • Raquel Capellán,
  • Gonzalo Castellanos,
  • Carlos Blas,
  • Laura Pardo,
  • Laura Solán,
  • Belén Rosado,
  • María Yuste,
  • Pilar Beltran,
  • Alberto Lázaro,
  • Ignacio Mahillo,
  • Eva Oliva,
  • Pilar Llamas,
  • Juan M. Alonso-Domínguez

摘要

The bone marrow microenvironment influences acute myeloid leukemia (AML) progression. Mesenchymal stem cell–like (MSC-l) populations may exert tumor-modulating effects, but their prognostic role remains uncertain. We retrospectively analyzed 65 adult AML patients (excluding acute promyelocytic leukemia) treated with intensive chemotherapy between 2017 and 2024 at four Spanish institutions. MSC-l cells were identified in BM aspirates at end of treatment by multiparameter flow cytometry (CD13bright/CD45low/CD34neg/CD117neg/CD11bneg/CD16neg/CD71neg/CD64neg). Patients were stratified using a 0.265%cutoff (MSC-lHIGH ≥ 0.265% and MSC-lLOW < 0.265%). Survival was assessed with Kaplan–Meier and Cox regression, adjusting for age and ELN 2017 risk. MSC-lHIGH patients had inferior overall survival (OS) (median 0.66 years vs. not reached; P < 0.001) and relapse-free survival (RFS) (median 1.27 years vs. 1.49 years; P = 0.027). These associations persisted across ELN risk groups. Multivariate analysis confirmed MSC-lHIGH status as an independent predictor of worse OS (HR = 6.43; 95% CI 2.53–16.33; P < 0.001) and RFS (HR = 4.8; 95% CI 1.71–13.47; P = 0.003). MSC-l levels were lower in patients receiving myeloablative conditioning compared with non-transplanted patients, suggesting transplant intensity may influence MSC dynamics. Higher post-treatment MSC-l proportions are associated with poorer survival, independent of ELN risk and age, supporting their potential as a prognostic biomarker in AML.